Once-Weekly Exenatide in Youth With Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Approved treatments for type 2 diabetes in pediatric patients include metformin, liraglutide, and insulin. However, approximately one-half of the youth fail metformin monotherapy within 1 year, insulin therapy is associated with challenges, and liraglutide requires daily injections. Consequently, the efficacy and safety of once-weekly injections of exenatide for the treatment of youth with type 2 diabetes was evaluated. RESEARCH DESIGN AND METHODS: Participants (aged 10 to <18 years) were randomized (5:2) to once-weekly exenatide 2 mg or placebo, respectively. The primary efficacy end point was change in glycated hemoglobin from baseline to week 24. Secondary efficacy end points were also evaluated, and the frequency of adverse events (AEs) was assessed. RESULTS: A total of 83 participants were randomized (exenatide, 59; placebo, 24) and 72 completed 24-week treatment (exenatide, 49; placebo, 23). At 24 weeks, the least squares mean change in glycated hemoglobin was −0.36% for the exenatide and +0.49% for the placebo groups (between-group difference, −0.85%; 95% CI −1.51, −0.19; P = 0.012). Nonsignificant least squares mean differences from baseline to 24 weeks favoring exenatide were observed: fasting glucose −21.6 mg/dL (−49.0, 5.7; P = 0.119), systolic blood pressure −2.8 mmHg (−8.0, 2.4; P = 0.284), and body weight −1.22 kg (−3.59, 1.15; P = 0.307). AEs occurred in 36 (61.0%) and 17 (73.9%) participants in the exenatide and placebo groups, respectively. CONCLUSIONS: In youth with type 2 diabetes suboptimally controlled with current treatments, once-weekly exenatide reduced glycated hemoglobin at 24 weeks and was well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 3×
“The definition of “major” hypoglycemia that was applied in the study is distinct from the current ADA definition (16,17) of “severe” hypoglycemia that was programmatically derived after the study had been completed.”
BackgroundInfluentialInternational Hypoglycaemia Study Group (2017) · Diabetes Care · doi:10.2337/dc16-2215 · Cited by 608
Effect of Metformin in Pediatric Patients With Type 2 Diabetes
Jones, K. L., Arslanian, S., Peterokova, V. A., Park, J.-S., & Tomlinson, M. J. (2002) · Diabetes Care · doi:10.2337/diacare.25.1.89 · Cited by 392
Youth-Onset Type 2 Diabetes Consensus Report: Current Status, Challenges, and Priorities
Nadeau, K. J., Anderson, B. J., Berg, E. G., Chiang, J. L., Chou, H., Copeland, K. C., Hannon, T. S., Huang, T. T.-K., Lynch, J. L., Powell, J., et al. (2016) · Diabetes Care · doi:10.2337/dc16-1066 · Cited by 381
Self-citationTODAY Study Group (2013) · Diabetes Care · doi:10.2337/dc12-2393 · Cited by 288
Insulin-associated weight gain in obese type 2 diabetes mellitus patients: What can be done?
Brown, A., Guess, N., Dornhorst, A., Taheri, S., & Frost, G. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13009 · Cited by 113
Care of diabetes in children and adolescents: controversies, changes, and consensus
Cameron, F. J., & Wherrett, D. K. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60971-0 · Cited by 99
Cited by
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker, D. J. (2024) · Diabetes Care · doi:10.2337/dci24-0003 · Cited by 383
14. Children and Adolescents: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s014 · Cited by 173
Managing early-onset type 2 diabetes in the individual and at the population level
Misra, S., Khunti, K., Goyal, A., Gable, D., Armocida, B., Tandon, N., Sachdev, P., Wild, S. H., Hivert, M.-F., & Beran, D. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01067-0 · Cited by 47
The efficacy and safety of GLP-1 receptor agonists in youth with type 2 diabetes: a meta-analysis
Yugar, L. B. T., Sedenho-Prado, L. G., da Silva Ferreira, I. M. C., Silva, C. A. M., Sposito, A. C., & Cercato, C. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01337-5 · Cited by 23
Metadata
- Authors
- Tamborlane, W. V., Bishai, R., Geller, D., Shehadeh, N., Al-Abdulrazzaq, D., Vazquez, E. M., Karoly, E., Troja, T., Doehring, O., Carter, D., Monyak, J., & Sjöström, C. D.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2022-07-26
- Volume
- 45
- Issue
- 8
- Pages
- 1833-1840
- ISSN
- 0149-5992 (ISSN-L)
- OpenAlex
- W4281788945
- Cited by
- 91
- References
- 7
- FWCI
- 11.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Once-Weekly Exenatide in Youth With Type 2 Diabetes. https://app.cochat.ai/papers/10.2337/dc21-2275
- The paper
- Tamborlane, W. V., Bishai, R., Geller, D., Shehadeh, N., Al-Abdulrazzaq, D., Vazquez, E. M., Karoly, E., Troja, T., Doehring, O., Carter, D., Monyak, J., & Sjöström, C. D. (2022). Once-Weekly Exenatide in Youth With Type 2 Diabetes. Diabetes Care. https://doi.org/10.2337/dc21-2275
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.